Progression of Loss of Vision From Centre‐Involving Macular Atrophy in Eyes Treated for nAMD
It is important to achieve disease inactivity in nAMD despite its association with incident MA, as neovascular complications play a significant role in VA loss. The long duration between the incidence of MA and clinically significant loss of vision offers an opportunity for potential interventions against atrophy.
Authors
- Louise O’Toole (ORCID: https://orcid.org/0000-0003-4851-0918)
- Alessandro Invernizzi (ORCID: https://orcid.org/0000-0003-3400-1987)
- Richard Barry (ORCID: https://orcid.org/0000-0002-0566-6667)
- Kelvin Yi Chong Teo (ORCID: https://orcid.org/0000-0002-7458-7081)
- Helena Brosa Morros (ORCID: https://orcid.org/0000-0002-8755-0923)
- Carolina Arruabarrena Sánchez
- Chui Ming Gemmy Cheung (ORCID: https://orcid.org/0000-0003-3358-3516)
- Theodorus Leonardus Ponsioen (ORCID: https://orcid.org/0000-0002-1414-836X)
- Shou‐Jen Lan (ORCID: https://orcid.org/0000-0002-2973-5428)
- Daniel Barthelmes
- Charmaine Chung
- Mark C. Gillies
Institutions
- Hebron University (PS)
- The University of Sydney (AU)
- University of Milan (IT)
- University of Zurich (CH)
- Singapore National Eye Center (SG)
- Gelre Hospitals (NL)
- Luigi Sacco Hospital (IT)
- University Hospital of Zurich (CH)
- Hospital Universitario Príncipe de Asturias (ES)
- Australian Pork (Australia) (AU)
- Singapore Eye Research Institute (SG)
- Vall d'Hebron Hospital Universitari (ES)
- Mater Private Hospital (AU)
- Isala (NL)
- Retina Clinic (BR)
Publication Details
- Journal
- Clinical and Experimental Ophthalmology
- Published
- 2025-08-03
- DOI
- https://doi.org/10.1111/ceo.14587
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71
Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- National Health and Medical Research Council